Sandu Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2025, Sandu Pharmaceuticals (SANDUPHQ) reported revenue ₹14 Cr and net profit ₹0 Cr — revenue -12.5% YoY. Also explore Sandu Pharmaceuticals share price performance to track price trends across different timeframes.
SANDUPHQ Quarterly Results — Revenue, Profit & EPS Highlights
Sandu Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with SANDUPHQ fair value to assess whether the stock is under or overvalued.
- Revenue of ₹14 Cr in Mar 2025 (-22.2% vs Sept 2024, -12.5% vs Mar 2024)
- EBITDA of ₹1 Cr in Mar 2025 (+0.0% vs Sept 2024)
- Operating Margin of 3.0% in Mar 2025 (-2.0pp vs Sept 2024)
- Earnings Per Share of ₹0.34 in Mar 2025 (-82.6% vs Sept 2024)
Sandu Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SANDUPHQ quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 14 | 18 | 16 | 17 | 18 | -22.2% | -12.5% |
| Net Profit (₹ Cr) | 0 | 1 | 1 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 1 | 1 | 1 | 0 | 1 | - | - |
| EPS (₹) | 0.34 | 1.95 | 0.62 | 0.17 | 0.57 | - | - |
| Operating Margin (%) | 3.0% | 5.0% | 4.0% | 2.0% | 5.0% | - | - |
SANDUPHQ Share Price Trend — 1-Year Movement Across Quarterly Results
Sandu Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SANDUPHQ share price.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SANDUPHQ vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sandu Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores